Migraine with aura
Drug research and approvals for migraine with aura: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 20 studies of migraine with aura are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 20
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in AdultsNCT07792681 · Phase 2 / Phase 3 · Brise Pharmaceuticals Co., Ltd. · starts Sep 30, 2026
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the…NCT07667621 · Phase 1 · University of South Florida · starts Sep 15, 2026
- Study of EVO756 in Adults With MigraineNCT07616128 · Phase 2 · Evommune, Inc. · starts Jul 29, 2026
- Yogabased Movements for Primary Headaches (Migraine and/or Cluster Headache) - YOURHEADNCT07348783 · Not applicable · Karolinska Institutet · starts May 1, 2026
- Neurogenetic And Hemodynamic Of Migraine Aura And PfoNCT07349004 · Not reported · Azienda Usl di Bologna · starts Nov 24, 2025
- New Methods for Evaluating Preventive Migraine TreatmentNCT07071506 · Not applicable · University of Aarhus · starts Jun 19, 2025
- Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients…NCT07022496 · Phase 4 · Ain Shams University · starts Apr 26, 2023
- Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related PeptideNCT07021859 · Not applicable · Danish Headache Center · starts Jun 27, 2025
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyNCT06972056 · Phase 4 · Mayo Clinic · starts Jul 9, 2025
Phase 3 8
- DihydroergotamineSerotonin 1d (5-HT1d) receptor agonist
- SumatriptanSerotonin 1b (5-HT1b) receptor agonist
- PromethazineHistamine H1 receptor antagonist
- RizatriptanSerotonin 1b (5-HT1b) receptor agonist
- EletriptanSerotonin 1f (5-HT1f) receptor agonist
- TizanidineAdrenergic receptor alpha-2 agonist
- CaffeineAdenosine receptor antagonist
- Anisodine hydrobromide
Phase 2 6
- Tonabersat
- PropranololBeta-1 adrenergic receptor antagonist
- AmilorideAmiloride-sensitive sodium channel, ENaC blocker
- RamelteonMelatonin receptor agonist
- DronabinolCannabinoid CB1 receptor agonist
- CandesartanType-1 angiotensin II receptor antagonist
Phase 1 or earlier 1
- SildenafilPhosphodiesterase 5A inhibitor
How its trials ended
99 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 22 whose ending is known, 64% met their primary endpoint, 9% missed it and 27% stopped early.
- Completed, result not reported4040%
- Ongoing2424%
- Met its primary endpoint1414%
- Status unknown1313%
- Stopped: enrollment or feasibility33%
- Missed its primary endpoint22%
- Stopped: other or unclear22%
- Stopped: lack of efficacy11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA